OptiScan Biomedical Corporation
PrivateLast Round
Series E
Mar 20, 2019
Total Funding Raised
$56M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
OptiScan Biomedical Corporation operates in Healthcare & Life Sciences and is based in Hayward, California. Its latest recorded funding round was a Series E round in March 2019.
OptiScan Biomedical Corporation is a medical device company that has developed an innovative monitoring platform for use in hospital intensive care units (ICUs) to support clinicians in detecting changes more rapidly in critically ill patients.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, Sensors
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OptiScan Biomedical Corporation Comparables
Compare OptiScan Biomedical Corporation with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GlucoSet | 77% | |
| Edwards Lifesciences | 76% | |
| Advanced Instruments | 73% |
For institutional investors. Book with your work email.
OptiScan Biomedical Corporation Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Mar 20, 2019 | ||||
| Series B | Oct 13, 2005 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
OptiScan Biomedical Corporation Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Prism Venture Partners | Series B |
| MedVenture Associates | Series B |
| NGN Capital | Series B |
| Morgenthaler Ventures | Series B |
| Sanders Morris Harris | Series B |
| Ascension Ventures | Series B |
| Wellcome Trust | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 226, 129% of headcount.
- Jun 30, 2026
Received Investors in People Gold accreditation.
For institutional investors. Book with your work email.
OptiScan Biomedical Corporation Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about OptiScan Biomedical Corporation's valuation, stock price, and market status.
Is OptiScan Biomedical Corporation a public or private company?
OptiScan Biomedical Corporation is a private company.
What is the current stock price of OptiScan Biomedical Corporation?
OptiScan Biomedical Corporation is a private company, so its shares have no public market price. Caplight tracks OptiScan Biomedical Corporation's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is OptiScan Biomedical Corporation worth (valuation)?
Valuation information for OptiScan Biomedical Corporation is not publicly available.
Can I buy OptiScan Biomedical Corporation stock?
OptiScan Biomedical Corporation shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was OptiScan Biomedical Corporation's last funding round?
OptiScan Biomedical Corporation's most recent funding round was Series E on March 20, 2019.
Who are the main investors in OptiScan Biomedical Corporation?
Key investors in OptiScan Biomedical Corporation include NGN Capital.
Will OptiScan Biomedical Corporation IPO soon?
No public IPO plans have been announced for OptiScan Biomedical Corporation.
How can I track OptiScan Biomedical Corporation secondary market activity?
Caplight tracks bids, offers, and trades in OptiScan Biomedical Corporation's shares on secondary markets.